<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/38E7D9DC-E2D5-40BF-8575-9301AB44C0DE"><gtr:id>38E7D9DC-E2D5-40BF-8575-9301AB44C0DE</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Hislop</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501074"><gtr:id>DED35B5B-E30C-4F61-9D02-E598DFA5B588</gtr:id><gtr:title>Immunity to gamma-herpesviruses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501074</gtr:grantReference><gtr:abstractText>Human herpes virus-8 (HHV-8 or Kaposis sarcoma associated herpes virus, KSHV) causes infections that people carry for life mostly with no ill effect. However, especially in people whose immune systems are suppressed, such as patients receiving bone marrow transplants after radiation treatment for leukaemia, or with the development of AIDS, this virus infection can get out of control and become life-threatening through the development of virus induced cancers. This reflects the important role that our immune system, especially that part of the immune system involving a type of white blood cell called a T cell, normally plays in controlling virus infections. We wish to study the way human T cells normally control HHV-8 infections and what parts of the virus are the main targets for T cell attack. HHV-8 is of interest to us as it contains proteins known to disrupt immune system recognition, however the impact these proteins have on the choice of target is not known, providing us with a natural model to examine the consequence of virus mediated subversion of the T cell response. In addition we wish to identify T cells that respond to a set of virus proteins which are only expressed by the cancers caused by this protein. The knowledge of these targets will be of particular importance for future studies understanding why some people do not control HHV-8 induced cancers with their T cells. Furthermore this information will allow us to make informed decisions as to the development of laboratory based strategies to target these responses and to the development of vaccines against this virus and the cancers associated with it.</gtr:abstractText><gtr:technicalSummary>Human herpes virus-8 (HHV-8, or Kaposis sarcoma associated herpes virus, KSHV) is a g-2 herpesvirus that infects endothelial and epithelial cells and, like the g-1 herpesvirus Epstein-Barr virus (EBV), B cells in which it establishes a reservoir of latently infected cells. Using the response to EBV lytic cycle antigens as a model, we have investigated the CD8 T cell immunodominance hierarchy of these proteins. We observed a bias in reactivities toward proteins expressed early in the replicative cycle and established a good correlation between the observed hierarchy and the ability of infected cells to present these epitopes. Little is known of the immunodominance hierarchy to HHV-8 lytic cycle proteins but would be of interest to determine this as HHV-8 encodes two known lytic cycle immune evasion genes, the effect of which on the lytic cycle immunodominance hierarchy is unknown. It would be of further interest to compare the HHV-8 immunodominance profile with that of EBV, where there is emerging evidence of a lytic cycle immune evasion function. We plan then to identify immunodominant HHV-8 lytic cycle-specific CD8 reactivities, using a strategy where recombinant adenoviruses or modified vaccinia Ankara expressing selected HHV-8 genes are used to stimulate HHV-8-specific CD8 T cells from HHV-8 infected individuals and use these reactivities to define HLA restrictions and identify epitopes. These epitopes will be used to quantitate responses by standard ELISpot and tetramer analysis, allowing the definition of the of the immunodominance hierarchy to lytic cycle antigens. We will generate HHV-8 T cell clones and use these as probes to examine the ability of these cells to recognise targets naturally replicating HHV-8 in an attempt to correlate immunodominance with antigen presentation. In a second arm of this work we plan to identify CD8 epitopes in latent cycle proteins that are expressed in HHV-8 associated malignancies using similar strategies. These epitopes will allow us to examine for evidence of immune focussing, like that seen in EBV latent-specific responses, and also serve as a basis for future investigations into understanding immune control of HHV-8 malignancies. In addition, one of these HHV-8 latent cycle proteins, LANA1, responsible for genome maintenance, has similarities to its EBV homologue, EBNA1: a protein that substantially inhibits its own antigen presentation. We plan to examine LANA1 for ability to prevent recognition of itself, by expressing LANA1 in cells and examining whether CD8 T cells can respond to epitopes contained within this protein.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>324922</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:department>MRC Unit, The Gambia</gtr:department><gtr:description>MRC Gambia sample collection and analysis</gtr:description><gtr:id>613EBAE1-8EB6-4D52-A06A-218BF4A87FA4</gtr:id><gtr:impact>The samples provided by our collaborators have allowed us to identify Kaposis sarcoma-associated herpesvirus T cell epitopes.</gtr:impact><gtr:outcomeId>E6641C25CEF-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided samples and conducted basic analysis on these before passing them on to us.</gtr:partnerContribution><gtr:piContribution>&amp;pound;27 048, unique project specific reagents and training of staff.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hosted CRUK supporters/donors to department</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F76AC979-A252-44E2-90D8-8973F87E4B1D</gtr:id><gtr:impact>40 supporters left inspired and encouraged to keep fundraising

None to my knowledge</gtr:impact><gtr:outcomeId>nkCAAsztjLZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>125278</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef>13-0102</gtr:fundingRef><gtr:id>0390EF2F-255B-4C82-B184-E6D60296C719</gtr:id><gtr:outcomeId>Qm6Cqt1xwfK</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have identified multiple T lymphocyte epitopes within Kaposis sarcoma-associated herpesvirus proteins that are expressed in malignancies associated with this virus infection.</gtr:description><gtr:id>31E3B364-1C1B-423B-99F7-C26C8BDFD8C4</gtr:id><gtr:impact>None as yet but the potential is there for the development of prophylactic and therapeutic vaccines and interventions, development of better diagnostics.</gtr:impact><gtr:outcomeId>1F6270553D4</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Kaposis sarcoma-associated herpesvirus T cell epitopes</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CFCEB43C-DF30-40F3-9587-E35479D2933D</gtr:id><gtr:title>EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fb8198871ffa3ada4c8c12e00fe628f"><gtr:id>4fb8198871ffa3ada4c8c12e00fe628f</gtr:id><gtr:otherNames>Horst D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>GzkVkuqcs3Q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A293075-E26A-4DC4-BB2E-AF6DF4EED11F</gtr:id><gtr:title>Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e09bcf346501396e9fdc1d487ed26a3"><gtr:id>4e09bcf346501396e9fdc1d487ed26a3</gtr:id><gtr:otherNames>Sauce D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>EC788CF02C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98BE740E-A4B4-42F7-8821-A2FF6F725F32</gtr:id><gtr:title>Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>NciHPtFyZZd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF6808D5-726C-4F51-9E13-9DE5EFC064CC</gtr:id><gtr:title>Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df47dbc2e09a70b6e4b08fa97fe8bd05"><gtr:id>df47dbc2e09a70b6e4b08fa97fe8bd05</gtr:id><gtr:otherNames>Misstear K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13441_21_22491458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B813102E-A096-452D-8C8D-C0CC35F9FAD8</gtr:id><gtr:title>Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>F5DB50CBE9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3519AA3B-13A1-4F6A-9B34-E72ACE9A7262</gtr:id><gtr:title>T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f5dac7f19ae78980fe985938e68ca20"><gtr:id>8f5dac7f19ae78980fe985938e68ca20</gtr:id><gtr:otherNames>Sabbah S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13441_21_22234686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>323B9FD2-5E7C-461C-9D3D-419980262B18</gtr:id><gtr:title>Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a9462b3c2e9848c5b748e53fd10bbcc"><gtr:id>9a9462b3c2e9848c5b748e53fd10bbcc</gtr:id><gtr:otherNames>Chaganti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>8BC37458312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE7FE510-166F-4817-8902-82DAE98FFAB9</gtr:id><gtr:title>Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45ee9f524afc1af2cb58609823aabd83"><gtr:id>45ee9f524afc1af2cb58609823aabd83</gtr:id><gtr:otherNames>Croft NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>1EE444030FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5E81A38-481D-4E96-8248-A485CDB767CB</gtr:id><gtr:title>An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b91a80d409f792102d2fa6e78e91532"><gtr:id>8b91a80d409f792102d2fa6e78e91532</gtr:id><gtr:otherNames>Bell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>85FC43E3786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7059E510-5591-41C2-AFD7-7BC8AF2E1855</gtr:id><gtr:title>The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6c242a2c0170e908a3a3ef84075a453"><gtr:id>f6c242a2c0170e908a3a3ef84075a453</gtr:id><gtr:otherNames>Njie R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>7360D938019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81488515-0B78-40BF-B4A6-3992DFA4A07B</gtr:id><gtr:title>CD8+ T cell immunity to Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus.</gtr:title><gtr:parentPublicationTitle>Seminars in cancer biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-579X</gtr:issn><gtr:outcomeId>BB4E2404310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE22FBF-0569-475B-BF78-2FACDDD9A6D2</gtr:id><gtr:title>Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cbff024946625fe40da562d041f695e"><gtr:id>8cbff024946625fe40da562d041f695e</gtr:id><gtr:otherNames>Palendira U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>qrDgSbthjc4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39322500-DC96-4E07-B001-DBFCBE3A04DE</gtr:id><gtr:title>Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cbff024946625fe40da562d041f695e"><gtr:id>8cbff024946625fe40da562d041f695e</gtr:id><gtr:otherNames>Palendira U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>A81F25F1A7F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B593F8-3302-41A4-9AA8-42302535320F</gtr:id><gtr:title>Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fb8198871ffa3ada4c8c12e00fe628f"><gtr:id>4fb8198871ffa3ada4c8c12e00fe628f</gtr:id><gtr:otherNames>Horst D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>A0E2D0D175B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04D6E440-BBC5-4F44-BC8F-9F8B35B2C9A0</gtr:id><gtr:title>IL-7R alpha versus CCR7 and CD45 as markers of virus-specific CD8+ T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e09bcf346501396e9fdc1d487ed26a3"><gtr:id>4e09bcf346501396e9fdc1d487ed26a3</gtr:id><gtr:otherNames>Sauce D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>CF4666F0FF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBF39B22-53AB-450F-8869-B0B59599AD8A</gtr:id><gtr:title>Synthesis and ex vivo profiling of chemically modified cytomegalovirus CMVpp65 epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of peptide science : an official publication of the European Peptide Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8674a6bd50f432812cf79d2814239b4e"><gtr:id>8674a6bd50f432812cf79d2814239b4e</gtr:id><gtr:otherNames>Jones MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1075-2617</gtr:issn><gtr:outcomeId>C95795A66FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C84B6209-EAB2-4231-B3CA-9E4E1A52C10E</gtr:id><gtr:title>The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72d96a4bcbdce942d350d62e762139ba"><gtr:id>72d96a4bcbdce942d350d62e762139ba</gtr:id><gtr:otherNames>Zuo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>PQ4HYqs94zL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8528262D-7BF9-4E47-A1C3-AA08207E3E99</gtr:id><gtr:title>A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>B132F7E1766</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501074</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>